Monkey ifabp fabp2 elisa kit

Plasma SAA1 and IFABP were quantified using a commercially available Monkey SAA1 ELISA kit (MyBioSource, San Diego, CA) and Monkey IFABP/FABP2 ELISA kit (MyBioSource, San Diego, CA) with 1:1000 and 1:2 sample dilution, respectively. Commercially available ELISA kits for Human CCL2/MCP-1 (R&D Systems, Minneapolis, MN), Human EndoCab IgM (Hycult Biotech, Plymouth Meeting, PA), and Human sCD14 (R&D Systems, Minneapolis, MN) were used according to the manufacturer’s protocols on plasma diluted 1:3, 1:100 and 1:300, respectively. Each sample was quantified in duplicate and analyzed with a 4-Parameter Logistic fit using the SoftMax Pro 6.4 program (Molecular Devices, Sunnyvale, CA). Differences between 0 and 8 DPI levels were evaluated for statistical significance using two-tailed Wilcoxon signed rank testing.

Different soluble markers were quantified in plasma of AGMs, using immuno-assays: sCD14 (Quantikine Human sCD14 Immunoassay, R&D Systems, Minneapolis, MN, USA), sCD163 (Macro163, IQProducts, Netherlands), I-FABP (Monkey I-FABP/FABP2 ELISA Kit, MyBioSource, San Diego, CA, USA) and CRP (Monkey CRP ELISA kit, Life Diagnostics, PA, USA). Expression of cytokines and chemokines was quantified using a magnetic bead-based assay, the Cytokine 29-plex Monkey Panel (Thermofisher), and plates were read on a MAGPIX® instrument. All ELISA and Luminex assays were performed according to manufacturer’s instructions. Due to the relatively small sample size and the relatively large interindividual variation for some analytes, the levels of all markers are expressed as a fold-change compared to preinfection levels that were determined on 2–3 preinfection samples for all AGMs.